Novel pharmaceutical treatments for minimal traumatic brain injury and evaluation of animal models and methodologies supporting their development

Keyphrases

• Traumatic Brain Injury 100%
• Minor Traumatic Brain Injury 100%
• Pharmaceutical Therapy 100%
• Novel Medications 100%
• Secondary Injury 66%
• Inflammation 33%
• Molecular Mechanism 33%
• Therapeutic Intervention 33%
• Apoptosis 33%
• Cognitive Deficits 33%
• Rodent Models 33%
• Rodents 33%
• Novel Object Recognition 33%
• Brain Injury 33%
• Older Adults 33%
• N-acetylation 33%
• Drug Target 33%
• Therapeutic Approaches 33%
• Thrombin 33%
• Preventive Measures 33%
• Degenerative Process 33%
• Clinical Efficacy 33%
• Neurotoxicity 33%
• Potential Therapeutics 33%
• Translational Relevance 33%
• Exendin-4 (Ex-4) 33%
• Traumatic Brain Injury Models 33%
• Blunt Trauma 33%
• Salubrinal 33%
• Translational Studies 33%
• Positive Treatment 33%

Neuroscience

• Neurotrauma 100%
• Traumatic Brain Injury 100%
• Cognitive Disorders 20%
• Brain Injury 20%
• In Vivo 20%
• Thrombin 20%
• Biochemical Cascade 20%
• Exenatide 20%
• Excitotoxicity 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Traumatic Brain Injury 100%
• Injury 40%
• Inflammation 20%
• Cognitive Defect 20%
• Acetic Acid Derivative 20%
• Thrombin 20%
• Drug 20%
• Blunt Trauma 20%
• Excitotoxicity 20%
• Exendin 4 20%
• Salubrinal 20%